Inari Medical (NARI) Stock Forecast, Price Target & Predictions
NARI Stock Forecast
Inari Medical stock forecast is as follows: an average price target of $65.63 (represents a -17.65% downside from NARI’s last price of $79.70) and a rating consensus of 'Hold', based on 12 wall street analysts offering a 1-year stock forecast.
NARI Price Target
The average price target for Inari Medical (NARI) is $65.63 based on 1-year price targets from 12 Wall Street analysts in the past 3 months, with a price target range of $86.00 to $50.00. This represents a potential -17.65% downside from NARI's last price of $79.70.
NARI Analyst Ratings
According to 12 Wall Street analysts, Inari Medical's rating consensus is 'Hold'. The analyst rating breakdown for NARI stock is 0 'Strong Buy' (0.00%), 5 'Buy' (41.67%), 6 'Hold' (50.00%), 0 'Sell' (0.00%), and 1 'Strong Sell' (8.33%).
Inari Medical Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Dec 18, 2024 | Richard Newitter | Truist Financial | $63.00 | $55.03 | 14.48% | -20.95% |
| Oct 29, 2024 | David Rescott | Robert W. Baird | $67.00 | $49.27 | 35.99% | -15.93% |
| Oct 29, 2024 | Adam Maeder | Piper Sandler | $52.00 | $42.56 | 22.18% | -34.76% |
| Oct 29, 2024 | William Plovanic | Canaccord Genuity | $74.00 | $42.56 | 73.87% | -7.15% |
| Oct 29, 2024 | Richard Newitter | Truist Financial | $50.00 | $42.56 | 17.48% | -37.26% |
| Oct 29, 2024 | Marie Thibault | BTIG | $86.00 | $42.56 | 102.07% | 7.90% |
| Oct 15, 2024 | David Rescott | Robert W. Baird | $66.00 | $42.20 | 56.40% | -17.19% |
| Sep 17, 2024 | Mathew Blackman | Stifel Nicolaus | $50.00 | $44.10 | 13.38% | -37.26% |
| Aug 09, 2024 | Pito Chickering | Deutsche Bank | $68.00 | $48.72 | 39.57% | -14.68% |
| Jul 31, 2024 | David Rescott | Robert W. Baird | $63.00 | $52.11 | 20.90% | -20.95% |
| Jul 31, 2024 | Larry Biegelsen | Wells Fargo | $65.00 | $52.11 | 24.74% | -18.44% |
| Jul 16, 2024 | Richard Newitter | Truist Financial | $60.00 | $54.97 | 9.15% | -24.72% |
| May 01, 2024 | Adam Maeder | Piper Sandler | $50.00 | $44.30 | 12.87% | -37.26% |
| Jan 06, 2023 | Morgan Stanley | $83.00 | $66.69 | 24.45% | 4.14% | |
| Dec 20, 2022 | Truist Financial | $75.00 | $67.13 | 11.73% | -5.90% | |
| Sep 16, 2022 | Canaccord Genuity | $94.00 | $68.64 | 36.94% | 17.94% | |
| Jul 15, 2022 | Morgan Stanley | $93.00 | $73.52 | 26.50% | 16.69% | |
| Jun 24, 2022 | BTIG | $100.00 | $72.32 | 38.27% | 25.47% |
The latest Inari Medical stock forecast, released on Dec 18, 2024 by Richard Newitter from Truist Financial, set a price target of $63.00, which represents a 14.48% increase from the stock price at the time of the forecast ($55.03), and a -20.95% decrease from NARI last price ($79.70).
Inari Medical Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 13 |
| Avg Price Target | - | $63.00 | $62.62 |
| Last Closing Price | $79.70 | $79.70 | $79.70 |
| Upside/Downside | -100.00% | -20.95% | -21.43% |
In the current month, the average price target of Inari Medical stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Inari Medical's last price of $79.70. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jan 07, 2025 | Jefferies | Hold | Downgrade | |
| Jan 07, 2025 | William Blair | Buy | Market Perform | Downgrade |
| Jan 07, 2025 | Piper Sandler | Neutral | Neutral | Hold |
| Dec 03, 2024 | BTIG | Buy | Buy | Hold |
| Oct 29, 2024 | Sandler O'Neill | Market Perform | Market Perform | Hold |
| Oct 29, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Oct 29, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Oct 29, 2024 | BTIG | Buy | Buy | Hold |
| Oct 09, 2024 | Wells Fargo | Market Perform | Market Perform | Hold |
| Oct 09, 2024 | Truist Financial | Underperform | Underperform | Hold |
| Sep 17, 2024 | Truist Financial | Underperform | Underperform | Hold |
| Sep 17, 2024 | Wells Fargo | Market Perform | Market Perform | Hold |
| Aug 26, 2024 | Truist Financial | Underperform | Underperform | Hold |
| Aug 26, 2024 | Wells Fargo | Buy | Buy | Hold |
| Aug 26, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Aug 09, 2024 | Deutsche Bank | Buy | Initialise | |
| Jul 31, 2024 | Wells Fargo | Overweight | Overweight | Hold |
| Jul 18, 2024 | Needham | Hold | Downgrade | |
| Jul 15, 2024 | Morgan Stanley | Outperform | Outperform | Hold |
| May 01, 2024 | Piper Sandler | Neutral | Neutral | Hold |
| Apr 12, 2024 | William Blair | Buy | Buy | Hold |
| Apr 12, 2024 | Truist Financial | Underperform | Underperform | Hold |
| Mar 22, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Mar 22, 2024 | Truist Financial | Buy | Buy | Hold |
| Feb 29, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Feb 29, 2024 | Truist Financial | Buy | Buy | Hold |
| Jan 06, 2023 | Morgan Stanley | Overweight | Overweight | Hold |
| Sep 16, 2022 | Canaccord Genuity | Buy | Buy | Hold |
| Jul 15, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Jun 24, 2022 | BTIG | Buy | Buy | Hold |
| Jun 21, 2022 | Piper Sandler | Overweight | Initialise | |
| Apr 26, 2022 | Zacks Investment Research | Strong Sell | Downgrade | |
| Feb 24, 2022 | Morgan Stanley | Overweight | Overweight | Hold |
| Feb 24, 2022 | SVB Leerink | Outperform | Outperform | Hold |
Inari Medical's last stock rating was published by Jefferies on Jan 07, 2025. The company Downgrade its NARI rating from "null" to "Hold".
Inari Medical Financial Forecast
Inari Medical Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | $132.09M | $126.37M | $119.00M | $116.17M | $107.77M | $96.20M | $92.74M | $86.75M | $83.22M | $72.92M | $63.45M | $57.40M | $48.61M | $38.72M | $25.39M |
| Avg Forecast | $224.39M | $214.63M | $205.03M | $199.06M | $187.56M | $178.97M | $170.10M | $166.68M | $160.69M | $150.69M | $143.79M | $137.83M | $131.79M | $121.92M | $116.67M | $110.56M | $104.85M | $90.83M | $87.80M | $83.60M | $78.15M | $63.04M | $59.65M | $55.14M | $42.87M | $26.53M | $12.97M |
| High Forecast | $227.68M | $217.78M | $208.03M | $201.97M | $190.31M | $181.59M | $172.59M | $168.93M | $161.63M | $150.85M | $143.79M | $137.83M | $132.03M | $121.92M | $118.38M | $112.18M | $106.14M | $90.83M | $87.80M | $83.60M | $78.15M | $63.04M | $59.65M | $55.14M | $42.87M | $26.53M | $12.97M |
| Low Forecast | $221.42M | $211.78M | $202.31M | $196.42M | $185.07M | $176.60M | $167.84M | $165.08M | $159.90M | $150.52M | $143.79M | $137.83M | $131.53M | $121.92M | $115.12M | $109.09M | $103.78M | $90.83M | $87.80M | $83.60M | $78.15M | $63.04M | $59.65M | $55.14M | $42.87M | $26.53M | $12.97M |
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 11 | 5 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 3 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.00% | 1.04% | 1.02% | 1.05% | 1.03% | 1.06% | 1.06% | 1.04% | 1.06% | 1.16% | 1.06% | 1.04% | 1.13% | 1.46% | 1.96% |
Inari Medical's average Quarter revenue forecast for Mar 24 based on 4 analysts is $137.83M, with a low forecast of $137.83M, and a high forecast of $137.83M. NARI's average Quarter revenue forecast represents a 4.34% increase compared to the company's last Quarter revenue of $132.09M (Dec 23).
Inari Medical EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 11 | 5 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 3 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | $-10.78M | $2.11M | $5.21M | $1.82M | $-2.84M | $-7.50M | $-7.04M | $-1.39M | $3.42M | $-1.67M | $5.01M | $8.53M | $7.51M | $7.11M | $-3.04M |
| Avg Forecast | $7.34M | $7.02M | $6.71M | $6.52M | $6.14M | $5.86M | $5.57M | $5.46M | $5.26M | $4.93M | $4.71M | $-1.90M | $4.31M | $3.99M | $3.82M | $-1.73M | $5.01M | $2.93M | $2.83M | $-1.85M | $2.52M | $2.03M | $1.92M | $5.63M | $1.38M | $854.94K | $-3.38M |
| High Forecast | $7.45M | $7.13M | $6.81M | $6.61M | $6.23M | $5.94M | $5.65M | $5.53M | $5.29M | $4.94M | $4.71M | $-1.52M | $4.32M | $3.99M | $3.87M | $-1.39M | $6.02M | $2.93M | $2.83M | $-1.48M | $2.52M | $2.03M | $1.92M | $6.75M | $1.38M | $854.94K | $-2.70M |
| Low Forecast | $7.25M | $6.93M | $6.62M | $6.43M | $6.06M | $5.78M | $5.49M | $5.40M | $5.23M | $4.93M | $4.71M | $-2.29M | $4.30M | $3.99M | $3.77M | $-2.08M | $4.01M | $2.93M | $2.83M | $-2.22M | $2.52M | $2.03M | $1.92M | $4.50M | $1.38M | $854.94K | $-4.06M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -2.50% | 0.53% | 1.36% | -1.05% | -0.57% | -2.56% | -2.49% | 0.75% | 1.36% | -0.82% | 2.61% | 1.52% | 5.44% | 8.31% | 0.90% |
7 analysts predict NARI's average Quarter EBITDA for Dec 23 to be $4.31M, with a high of $4.32M and a low of $4.30M. This is 104.13% upper than Inari Medical's previous annual EBITDA (Sep 23) of $2.11M.
Inari Medical Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 11 | 5 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 3 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | $-4.67M | $3.16M | $2.08M | $-2.22M | $-5.80M | $-10.15M | $-10.19M | $-3.18M | $1.11M | $-2.80M | $4.07M | $7.47M | $6.99M | $6.50M | $-3.80M |
| Avg Forecast | $6.99M | $5.86M | $5.37M | $2.92M | $4.55M | $3.21M | $879.23K | $-1.56M | $-1.12M | $-6.77M | $-11.27M | $-4.29M | $358.37K | $802.54K | $-7.33M | $-3.90M | $1.62M | $-14.41M | $-13.37M | $-4.17M | $2.18M | $-3.97M | $4.77M | $4.93M | $727.25K | $-2.21M | $-4.23M |
| High Forecast | $7.12M | $5.97M | $5.48M | $2.97M | $4.64M | $3.27M | $895.98K | $3.12M | $777.99K | $-6.65M | $-11.08M | $-3.43M | $2.87M | $809.83K | $-7.20M | $-3.12M | $1.95M | $-14.41M | $-13.37M | $-3.34M | $2.18M | $-3.97M | $4.77M | $5.92M | $727.25K | $-2.21M | $-3.38M |
| Low Forecast | $6.87M | $5.76M | $5.28M | $2.87M | $4.48M | $3.15M | $864.08K | $-6.24M | $-6.22M | $-6.90M | $-11.48M | $-5.15M | $-1.43M | $795.24K | $-7.47M | $-4.68M | $1.30M | $-14.41M | $-13.37M | $-5.01M | $2.18M | $-3.97M | $4.77M | $3.94M | $727.25K | $-2.21M | $-5.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -13.02% | 3.94% | -0.28% | 0.57% | -3.57% | 0.70% | 0.76% | 0.76% | 0.51% | 0.71% | 0.85% | 1.52% | 9.60% | -2.94% | 0.90% |
Inari Medical's average Quarter net income forecast for Dec 23 is $358.37K, with a range of $-1.43M to $2.87M. NARI's average Quarter net income forecast represents a -88.67% decrease compared to the company's last Quarter net income of $3.16M (Sep 23).
Inari Medical SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 11 | 5 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 3 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | $101.49M | $88.28M | $85.59M | $85.70M | $80.12M | $75.83M | $73.16M | $63.73M | $54.47M | $56.10M | $42.90M | $36.90M | $31.39M | $23.08M | $18.88M |
| Avg Forecast | $159.43M | $152.49M | $145.67M | $141.43M | $133.26M | $127.16M | $120.85M | $118.42M | $114.17M | $107.06M | $102.16M | $87.40M | $93.63M | $86.63M | $82.89M | $79.45M | $79.88M | $63.94M | $61.81M | $58.85M | $55.01M | $44.37M | $41.99M | $24.35M | $30.17M | $18.68M | $9.13M |
| High Forecast | $161.76M | $154.73M | $147.80M | $143.50M | $135.21M | $129.02M | $122.62M | $120.03M | $114.84M | $107.18M | $102.16M | $104.88M | $93.80M | $86.63M | $84.11M | $95.34M | $95.86M | $63.94M | $61.81M | $58.85M | $55.01M | $44.37M | $41.99M | $29.22M | $30.17M | $18.68M | $9.13M |
| Low Forecast | $157.31M | $150.47M | $143.74M | $139.55M | $131.49M | $125.47M | $119.25M | $117.29M | $113.61M | $106.94M | $102.16M | $69.92M | $93.45M | $86.63M | $81.79M | $63.56M | $63.91M | $63.94M | $61.81M | $58.85M | $55.01M | $44.37M | $41.99M | $19.48M | $30.17M | $18.68M | $9.13M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | 1.08% | 1.02% | 1.03% | 1.08% | 1.00% | 1.19% | 1.18% | 1.08% | 0.99% | 1.26% | 1.02% | 1.52% | 1.04% | 1.24% | 2.07% |
Inari Medical's average Quarter SG&A projection for Mar 24 is $87.40M, based on 4 Wall Street analysts, with a range of $69.92M to $104.88M. The forecast indicates a -13.89% fall compared to NARI last annual SG&A of $101.49M (Dec 23).
Inari Medical EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 4 | 5 | 4 | 5 | 2 | 7 | 11 | 5 | 3 | 4 | 7 | 5 | 6 | 3 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | 6 | 6 | 3 | 3 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | $-0.08 | $0.06 | $0.04 | $-0.04 | $-0.11 | $-0.19 | $-0.19 | $-0.06 | $0.02 | $-0.06 | $0.08 | $0.15 | $0.14 | $0.13 | $-0.16 |
| Avg Forecast | $0.12 | $0.10 | $0.09 | $0.05 | $0.08 | $0.05 | $0.02 | $-0.03 | $-0.02 | $-0.12 | $-0.19 | $-0.16 | $0.01 | $0.01 | $-0.13 | $-0.23 | $-0.17 | $-0.25 | $-0.23 | $-0.08 | $0.04 | $-0.07 | $0.08 | $0.06 | $0.01 | $-0.04 | $-0.17 |
| High Forecast | $0.12 | $0.10 | $0.09 | $0.05 | $0.08 | $0.06 | $0.02 | $0.05 | $0.01 | $-0.11 | $-0.19 | $-0.15 | $0.05 | $0.01 | $-0.12 | $-0.22 | $-0.17 | $-0.25 | $-0.23 | $-0.08 | $0.04 | $-0.07 | $0.08 | $0.06 | $0.01 | $-0.04 | $-0.17 |
| Low Forecast | $0.12 | $0.10 | $0.09 | $0.05 | $0.08 | $0.05 | $0.01 | $-0.11 | $-0.11 | $-0.12 | $-0.20 | $-0.16 | $-0.02 | $0.01 | $-0.13 | $-0.23 | $-0.17 | $-0.25 | $-0.23 | $-0.08 | $0.04 | $-0.07 | $0.08 | $0.06 | $0.01 | $-0.04 | $-0.17 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | -13.39% | 4.01% | -0.32% | 0.18% | 0.64% | 0.77% | 0.83% | 0.80% | 0.59% | 0.88% | 0.98% | 2.65% | 11.19% | -3.42% | 0.91% |
According to 7 Wall Street analysts, Inari Medical's projected average Quarter EPS for Dec 23 is $0.01, with a low estimate of $-0.02 and a high estimate of $0.05. This represents a -88.86% decrease compared to NARI previous annual EPS of $0.06 (Sep 23).